Acusphere's Imagify to get FDA review

By staff writers

October 13, 2008 -- Ultrasound contrast developer Acusphere said that its Imagify contrast agent will be reviewed during a planned public meeting of the U.S. Food and Drug Administration (FDA)'s Cardiovascular and Renal Drugs Advisory Committee on December 10.

Imagify has a proposed indication for patients with stable chest pain being evaluated for inducible ischemia for the detection of coronary artery disease based on assessment of myocardial perfusion and wall motion, according to the Watertown, MA-based firm.

Acusphere taps new VP, September 25, 2008

Acusphere receives Nasdaq noncompliance notice, August 14, 2008

Acusphere reports Q2 results, August 12, 2008

Acusphere cuts staff, July 29, 2008

Acusphere gets Nasdaq warning letter, July 15, 2008

Copyright © 2008


To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking